1 Introduction to Research & Analysis Reports
1.1 Biosimilars Insulin Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Biosimilars Insulin Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Biosimilars Insulin Overall Market Size
2.1 Global Biosimilars Insulin Market Size: 2022 VS 2029
2.2 Global Biosimilars Insulin Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Biosimilars Insulin Sales: 2018-2029
3 Company Landscape
3.1 Top Biosimilars Insulin Players in Global Market
3.2 Top Global Biosimilars Insulin Companies Ranked by Revenue
3.3 Global Biosimilars Insulin Revenue by Companies
3.4 Global Biosimilars Insulin Sales by Companies
3.5 Global Biosimilars Insulin Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Biosimilars Insulin Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Biosimilars Insulin Product Type
3.8 Tier 1, Tier 2 and Tier 3 Biosimilars Insulin Players in Global Market
3.8.1 List of Global Tier 1 Biosimilars Insulin Companies
3.8.2 List of Global Tier 2 and Tier 3 Biosimilars Insulin Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Biosimilars Insulin Market Size Markets, 2022 & 2029
4.1.2 Insulin Glargine
4.1.3 Insulin Aspart
4.1.4 Insulin Lispro
4.1.5 Other
4.2 By Type – Global Biosimilars Insulin Revenue & Forecasts
4.2.1 By Type – Global Biosimilars Insulin Revenue, 2018-2023
4.2.2 By Type – Global Biosimilars Insulin Revenue, 2024-2029
4.2.3 By Type – Global Biosimilars Insulin Revenue Market Share, 2018-2029
4.3 By Type – Global Biosimilars Insulin Sales & Forecasts
4.3.1 By Type – Global Biosimilars Insulin Sales, 2018-2023
4.3.2 By Type – Global Biosimilars Insulin Sales, 2024-2029
4.3.3 By Type – Global Biosimilars Insulin Sales Market Share, 2018-2029
4.4 By Type – Global Biosimilars Insulin Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Biosimilars Insulin Market Size, 2022 & 2029
5.1.2 Type I Diabetes
5.1.3 Type II Diabetes
5.2 By Application – Global Biosimilars Insulin Revenue & Forecasts
5.2.1 By Application – Global Biosimilars Insulin Revenue, 2018-2023
5.2.2 By Application – Global Biosimilars Insulin Revenue, 2024-2029
5.2.3 By Application – Global Biosimilars Insulin Revenue Market Share, 2018-2029
5.3 By Application – Global Biosimilars Insulin Sales & Forecasts
5.3.1 By Application – Global Biosimilars Insulin Sales, 2018-2023
5.3.2 By Application – Global Biosimilars Insulin Sales, 2024-2029
5.3.3 By Application – Global Biosimilars Insulin Sales Market Share, 2018-2029
5.4 By Application – Global Biosimilars Insulin Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Biosimilars Insulin Market Size, 2022 & 2029
6.2 By Region – Global Biosimilars Insulin Revenue & Forecasts
6.2.1 By Region – Global Biosimilars Insulin Revenue, 2018-2023
6.2.2 By Region – Global Biosimilars Insulin Revenue, 2024-2029
6.2.3 By Region – Global Biosimilars Insulin Revenue Market Share, 2018-2029
6.3 By Region – Global Biosimilars Insulin Sales & Forecasts
6.3.1 By Region – Global Biosimilars Insulin Sales, 2018-2023
6.3.2 By Region – Global Biosimilars Insulin Sales, 2024-2029
6.3.3 By Region – Global Biosimilars Insulin Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Biosimilars Insulin Revenue, 2018-2029
6.4.2 By Country – North America Biosimilars Insulin Sales, 2018-2029
6.4.3 US Biosimilars Insulin Market Size, 2018-2029
6.4.4 Canada Biosimilars Insulin Market Size, 2018-2029
6.4.5 Mexico Biosimilars Insulin Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Biosimilars Insulin Revenue, 2018-2029
6.5.2 By Country – Europe Biosimilars Insulin Sales, 2018-2029
6.5.3 Germany Biosimilars Insulin Market Size, 2018-2029
6.5.4 France Biosimilars Insulin Market Size, 2018-2029
6.5.5 U.K. Biosimilars Insulin Market Size, 2018-2029
6.5.6 Italy Biosimilars Insulin Market Size, 2018-2029
6.5.7 Russia Biosimilars Insulin Market Size, 2018-2029
6.5.8 Nordic Countries Biosimilars Insulin Market Size, 2018-2029
6.5.9 Benelux Biosimilars Insulin Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Biosimilars Insulin Revenue, 2018-2029
6.6.2 By Region – Asia Biosimilars Insulin Sales, 2018-2029
6.6.3 China Biosimilars Insulin Market Size, 2018-2029
6.6.4 Japan Biosimilars Insulin Market Size, 2018-2029
6.6.5 South Korea Biosimilars Insulin Market Size, 2018-2029
6.6.6 Southeast Asia Biosimilars Insulin Market Size, 2018-2029
6.6.7 India Biosimilars Insulin Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Biosimilars Insulin Revenue, 2018-2029
6.7.2 By Country – South America Biosimilars Insulin Sales, 2018-2029
6.7.3 Brazil Biosimilars Insulin Market Size, 2018-2029
6.7.4 Argentina Biosimilars Insulin Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Biosimilars Insulin Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Biosimilars Insulin Sales, 2018-2029
6.8.3 Turkey Biosimilars Insulin Market Size, 2018-2029
6.8.4 Israel Biosimilars Insulin Market Size, 2018-2029
6.8.5 Saudi Arabia Biosimilars Insulin Market Size, 2018-2029
6.8.6 UAE Biosimilars Insulin Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Company Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Biosimilars Insulin Major Product Offerings
7.1.4 Eli Lilly Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.1.5 Eli Lilly Key News & Latest Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Summary
7.2.2 Boehringer Ingelheim Business Overview
7.2.3 Boehringer Ingelheim Biosimilars Insulin Major Product Offerings
7.2.4 Boehringer Ingelheim Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.2.5 Boehringer Ingelheim Key News & Latest Developments
7.3 Biocon/Mylan
7.3.1 Biocon/Mylan Company Summary
7.3.2 Biocon/Mylan Business Overview
7.3.3 Biocon/Mylan Biosimilars Insulin Major Product Offerings
7.3.4 Biocon/Mylan Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.3.5 Biocon/Mylan Key News & Latest Developments
7.4 Gan & Lee Pharmaceuticals
7.4.1 Gan & Lee Pharmaceuticals Company Summary
7.4.2 Gan & Lee Pharmaceuticals Business Overview
7.4.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Major Product Offerings
7.4.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.4.5 Gan & Lee Pharmaceuticals Key News & Latest Developments
7.5 Tonghua Dongbao
7.5.1 Tonghua Dongbao Company Summary
7.5.2 Tonghua Dongbao Business Overview
7.5.3 Tonghua Dongbao Biosimilars Insulin Major Product Offerings
7.5.4 Tonghua Dongbao Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.5.5 Tonghua Dongbao Key News & Latest Developments
7.6 United Laboratories
7.6.1 United Laboratories Company Summary
7.6.2 United Laboratories Business Overview
7.6.3 United Laboratories Biosimilars Insulin Major Product Offerings
7.6.4 United Laboratories Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.6.5 United Laboratories Key News & Latest Developments
7.7 Sanofi
7.7.1 Sanofi Company Summary
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Biosimilars Insulin Major Product Offerings
7.7.4 Sanofi Biosimilars Insulin Sales and Revenue in Global (2018-2023)
7.7.5 Sanofi Key News & Latest Developments
8 Global Biosimilars Insulin Production Capacity, Analysis
8.1 Global Biosimilars Insulin Production Capacity, 2018-2029
8.2 Biosimilars Insulin Production Capacity of Key Manufacturers in Global Market
8.3 Global Biosimilars Insulin Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Biosimilars Insulin Supply Chain Analysis
10.1 Biosimilars Insulin Industry Value Chain
10.2 Biosimilars Insulin Upstream Market
10.3 Biosimilars Insulin Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Biosimilars Insulin Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界のバイオシミラーインスリン市場予測2023-2029：インスリングラルギン、インスリンアスパルト、インスリンリスプロ、その他 |
| 【英語タイトル】Biosimilars Insulin Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5718 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：79 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界のバイオシミラーインスリン市場規模と予測を収録しています。・世界のバイオシミラーインスリン市場：売上、2018年-2023年、2024年-2029年 ・世界のバイオシミラーインスリン市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のバイオシミラーインスリン市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「インスリングラルギン」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 バイオシミラーインスリンのグローバル主要企業は、Eli Lilly、 Boehringer Ingelheim、 Biocon/Mylan、 Gan & Lee Pharmaceuticals、 Tonghua Dongbao、 United Laboratories、 Sanofiなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、バイオシミラーインスリンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のバイオシミラーインスリン市場：タイプ別、2018年-2023年、2024年-2029年 世界のバイオシミラーインスリン市場：タイプ別市場シェア、2022年 ・インスリングラルギン、インスリンアスパルト、インスリンリスプロ、その他 世界のバイオシミラーインスリン市場：用途別、2018年-2023年、2024年-2029年 世界のバイオシミラーインスリン市場：用途別市場シェア、2022年 ・Ⅰ型糖尿病、Ⅱ型糖尿病 世界のバイオシミラーインスリン市場：地域・国別、2018年-2023年、2024年-2029年 世界のバイオシミラーインスリン市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるバイオシミラーインスリンのグローバル売上、2018年-2023年 ・主要企業におけるバイオシミラーインスリンのグローバル売上シェア、2022年 ・主要企業におけるバイオシミラーインスリンのグローバル販売量、2018年-2023年 ・主要企業におけるバイオシミラーインスリンのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Eli Lilly、 Boehringer Ingelheim、 Biocon/Mylan、 Gan & Lee Pharmaceuticals、 Tonghua Dongbao、 United Laboratories、 Sanofi ************************************************************* ・調査・分析レポートの概要 バイオシミラーインスリン市場の定義 市場セグメント 世界のバイオシミラーインスリン市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のバイオシミラーインスリン市場規模 世界のバイオシミラーインスリン市場規模：2022年 VS 2029年 世界のバイオシミラーインスリン市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのバイオシミラーインスリンの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のバイオシミラーインスリン製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：インスリングラルギン、インスリンアスパルト、インスリンリスプロ、その他 バイオシミラーインスリンのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：Ⅰ型糖尿病、Ⅱ型糖尿病 バイオシミラーインスリンの用途別グローバル売上・予測 ・地域別市場分析 地域別バイオシミラーインスリン市場規模 2022年と2029年 地域別バイオシミラーインスリン売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Eli Lilly、 Boehringer Ingelheim、 Biocon/Mylan、 Gan & Lee Pharmaceuticals、 Tonghua Dongbao、 United Laboratories、 Sanofi ... |
Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
This report aims to provide a comprehensive presentation of the global market for Biosimilars Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars Insulin. This report contains market size and forecasts of Biosimilars Insulin in global, including the following market information:
Global Biosimilars Insulin Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Biosimilars Insulin Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Biosimilars Insulin companies in 2022 (%)
The global Biosimilars Insulin market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim’s biosimilar insulin glargine has got approval through European Medicines Agency’s (EMA’s) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Biosimilars Insulin manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biosimilars Insulin Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, by Type, 2022 (%)
Insulin Glargine
Insulin Aspart
Insulin Lispro
Other
Global Biosimilars Insulin Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, by Application, 2022 (%)
Type I Diabetes
Type II Diabetes
Global Biosimilars Insulin Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biosimilars Insulin Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biosimilars Insulin revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Biosimilars Insulin revenues share in global market, 2022 (%)
Key companies Biosimilars Insulin sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Biosimilars Insulin sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly
Boehringer Ingelheim
Biocon/Mylan
Gan & Lee Pharmaceuticals
Tonghua Dongbao
United Laboratories
Sanofi
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biosimilars Insulin, market overview.
Chapter 2: Global Biosimilars Insulin market size in revenue and volume.
Chapter 3: Detailed analysis of Biosimilars Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biosimilars Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Biosimilars Insulin capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界のバイオシミラーインスリン市場予測2023-2029：インスリングラルギン、インスリンアスパルト、インスリンリスプロ、その他] (コード：MMG23JU5718)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界のバイオシミラーインスリン市場予測2023-2029：インスリングラルギン、インスリンアスパルト、インスリンリスプロ、その他]についてメールでお問い合わせ |
